Full Breakdown
Merck and Moderna Report Positive Phase 3 Results for Personalized Melanoma Vaccine
8/20/2026, 6:05:48 AM
Core Event
On August 19, Merck and Moderna announced interim results from a Phase 3 trial of their personalized mRNA cancer vaccine, Intismeran, given with Merck’s immunotherapy Keytruda (pembrolizumab). The study met its primary endpoint of recurrence-free survival and its secondary endpoint of distant-metastasis-free survival, showing a statistically significant reduction in both melanoma recurrence and spread compared with Keytruda alone.
Background & Context
Melanoma, the deadliest form of skin cancer, accounts for most skin-cancer deaths despite representing only about 1 % of cases. Traditional treatments have included surgery, radiation, chemotherapy, and checkpoint-inhibitor immunotherapies such as Keytruda. Over the past decade, researchers have adapted messenger-RNA (mRNA) platforms—first popularized by COVID-19 vaccines—to create individualized cancer vaccines that encode patient-specific tumor mutations (neoantigens). Intismeran is the first mRNA-based vaccine of this type to reach a late-stage trial.
Data & Statistics
- Trial size: 1,137 high-risk patients with stage IIB-IV melanoma whose tumors had been surgically removed.
- Risk reduction: Interim data indicate a 49 % lower risk of recurrence or death and a 59 % lower risk of distant metastasis compared with Keytruda alone.
- U.S. burden: More than 1.5 million Americans were living with melanoma in 2023, according to the National Cancer Institute.
Official Statements & Responses
- Stephen Hoge, president of Moderna, called the result “a landmark” and noted that the vaccine’s breakthrough-therapy designation could allow regulatory filing as early as next year.
- Dean Y. Li, president of Merck Research Laboratories, said the data demonstrate the value of intervening earlier in the disease course.
- Falyn Katz, CEO of Melanoma Canada, described the interim results “incredibly encouraging” while noting that full data are still pending.
Verbatim Quotes
- “This is the first time that we've seen really clinically significant, statistically significant improvements over checkpoints like Keytruda in this population, and it is the first time we've done that with an individualized treatment,” — Stephen Hoge
- “These first Phase 3 findings for intismeran in combination with KEYTRUDA as adjuvant therapy reinforce the promise of a more personalized approach to cancer treatment,” — Dean Y. Li
- “First, we need to establish how much additional benefit the personalized mRNA therapy provides compared with established adjuvant immunotherapy.” — Kim Margolin
What’s Next
Merck and Moderna plan to present the full dataset at an upcoming international medical conference and to begin formal discussions with regulators in the next few months. A regulatory submission could be filed as early as next year, pending final analysis of overall survival and safety outcomes.
*This article synthesizes information from multiple news reports and press releases released on August 19, 2026.*
